NCT06642571View on ClinicalTrials.gov

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

May 17, 2025

Study Completion Date

May 31, 2025

Conditions
Obesity
Interventions
DRUG

NNC0519-0130 B

NNC0519-0130 B will be administered subcutaneously.

DRUG

NNC0519-0130 C

NNC0519-0130 C will be administered subcutaneously.

Trial Locations (1)

78209

ICON, San Antonio

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY